Skip to Main Content

Paper Details

Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors.
Clin Cancer Res
51
2021
-, BRCA, BRCA-deficient cancers, BRCA-mutant, BRCA1, CHK1, Checkpoint kinase 1, H2AX, HGSOC, HR proficiency, High-grade Serous Ovarian Cancer, Olaparib, PARP, PATIENTS, Patients, Prexasertib, RAD51, RAD51 foci, Solid Tumors, anemia, febrile neutropenia, high-grade serous ovarian cancer, leukopenia, neutropenia, olaparib, pKAP1, pRPA, patients, prexasertib, thrombocytopenia, tumor
Author NameAffiliation
Alan D D'AndreaCenter for DNA Damage and Repair, Dana-Farber Cancer Institute
Alan D D'AndreaDana-Farber Cancer Institute and Harvard Medical School
Alan D D'AndreaCenter for DNA Damage and Repair, Dana-Farber Cancer Institute
Alan D D'AndreaDana-Farber Cancer Institute and Harvard Medical School
  • 1 - 4

Datasets

Release 1.2